Dataset opportunity
Mimetas — Medical Imaging Dataset Opportunity
Large medical imaging dataset held by Mimetas, usable for Diagnostic AI and Computer Vision.
Score
48
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
65%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global Organ-on-a-Chip market was valued at $147 Million in 2024, projected to grow at a CAGR of 29.7% from 2025–2034.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Large
Freshness
Real-time
Rarity
Medium
Accessibility
Restricted
Legal
Owned by the company — clean to license · PII/regulated
Buyer persona
Medical-AI & diagnostic-imaging companies
Mimetas holds a unique Medical Imaging Dataset generated from its proprietary OrganoPlate® platform, which enables high-throughput 3D cell culture. The data consists of high-resolution 3D imaging and biological assay results from in-vitro organoids, providing a detailed view of tissue morphology, cell viability, and protein localization. This highly specific and structured dataset is exceptionally well-suited for training and validating Diagnostic AI models aimed at predicting drug toxicity and efficacy in a human-relevant context before clinical trials.
The dataset's value is directly tied to the rapidly expanding Organ-on-a-Chip market, which was valued at USD 147 million in 2024 and is projected to grow at a remarkable CAGR of 29.7% to reach USD 2.1 billion by 2034. While access is complex due to the data's highly technical nature, potential IP overlaps with partners, and its unique proprietary format, its rarity and direct applicability to this high-growth sector make it an invaluable asset for developing next-generation predictive health technologies. ⚠ Diligence (valuable data, access to negotiate): Data is highly technical (biological assays and 3D imaging); Potential IP overlap with pharmaceutical partners in co-development projects; Proprietary OrganoPlate hardware creates a unique data format/standard · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Evidence confirms Mimetas possesses a proprietary dataset of 3D tissue model images, generated for pre-clinical analysis of compound safety and pharmacokinetics. This unique imagery is essential for training next-generation diagnostic AI and offers a significant competitive advantage in the rapidly growing Organ-on-a-Chip market, projected to expand at a CAGR of nearly 30%. For medical AI firms, this dataset represents a direct path to developing predictive models that accelerate drug discovery and reduce reliance on traditional testing.
See dimension details ↓- Right to License92
ownership=company_owned, licensing=clean
Whether the company can legally license the data out — based on ownership and licensing complexity. - Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume70
6 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is extremely high, driven by the urgent need for more predictive, human-relevant models in a market growing at a 29.7% CAGR, accelerated by regulatory shifts away from animal testing.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility44
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength89
5 evidence types, 6 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit67
⚠ review — Mimetas' core business is selling organ-on-a-chip products and associated contract research services, including AI-powered analytics, making it a seller of intelligence, not a holder of dormant data. Issues: Company's core business is selling products (OrganoPlate) and contract research services (OrganoServices, Custom Services) which include generating and analyzin; The company explicitly offers 'AI- and machine learning–powered analytics' to provide 'clear, actionable answers' from complex datasets as part of its value pro; Mimetas was recently acquired by Bruker, a large analytical instrument company, to integrate its human models with Bruker's data analysis technologies, reinforc; The company's business model is to provide 'actionable data' and 'deep disease insights' to pharmaceutical companies, which is a form of selling intelligence.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
Mimetas provides detailed protocol documentation and metadata, ensuring any acquired imaging data is well-contextualized and suitable for training robust AI on high-throughput screening results.
Public datasets
The company generates analytical datasets from its experiments, offering structured, tabular data ideal for companies developing complementary machine learning models.
Image collection
The core asset is a collection of proprietary images from complex 3D tissue models, providing the rich, multiplexed data needed to train advanced diagnostic AI on cellular and tissue-level interactions.
IoT / sensor data
The dataset includes real-time sensor data from the proprietary OrganoTEER® platform, enabling the creation of predictive time-series models that correlate physical measurements with visual outcomes.
Medical records / imaging
This evidence points to a collection of pre-clinical images used to generate human-relevant insights, directly supporting AI models focused on predicting pharmacokinetics and compound safety.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Mimetas Medical Imaging — a Large medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global Organ-on-a-Chip market was valued at $147 Million in 2024, projected to grow at a CAGR of 29.7% from 2025–2034 (source: GMI Insights).. Investment score 48.0/100 (confidence 0.65). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Adipogen — Industrial Operations Dataset Opportunity
View opportunity →healthcareElevationspine — Medical Imaging Dataset Opportunity
View opportunity →healthcareBluewindmedical — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- What you are entitled to sell3 min read
- 5 Mistakes That Drive Buyers Away3 min read
- Why Buy External Data?3 min read